Cost-Effectiveness of Nivolumab in Combination with Ipilimumab in First-Line Treatment of Advanced Melanoma in Three European Countries Using 28-Month Overall Survival from Checkmate 067
Abstract
Authors
A Hirst VF Paly F Diamantogiannis C Guilmet S C Polanco J Sabater O Chirita